Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-2094
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia ; volume:17 ; number:1 ; day:17 ; month:8 ; year:2020 ; pages:1-16 ; date:12.2020
Journal of neuroinflammation ; 17, Heft 1 (17.8.2020), 1-16, 12.2020
- Creator
-
Rivas-Santisteban, Rafael
Rodriguez-Perez, Ana I.
Muñoz, Ana
Reyes-Resina, Irene
Labandeira-García, José Luis
Navarro, Gemma
Franco, Rafael
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12974-020-01908-z
- URN
-
urn:nbn:de:101:1-2020100900344849067600
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rivas-Santisteban, Rafael
- Rodriguez-Perez, Ana I.
- Muñoz, Ana
- Reyes-Resina, Irene
- Labandeira-García, José Luis
- Navarro, Gemma
- Franco, Rafael
- SpringerLink (Online service)
Other Objects (12)
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis